Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
45 hedge funds and large institutions have $123M invested in Eiger BioPharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 9 closing their positions.
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
40% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 10
13% more funds holding
Funds holding: 40 → 45 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $128M → $123M (-$5.13M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$13.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.8M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$4.4M |
| 4 |
Axa
Paris,
France
|
+$2.88M |
| 5 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$518K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$434K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$301K |
| 4 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$290K |
| 5 |
Goldman Sachs
New York
|
-$219K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Goldman Sachs
New York
| – | -$219K | -30 | Closed |
|
|
LP
52
LMR Partners
London,
United Kingdom
| – | -$219K | -30 | Closed |
|
53
Millennium Management
New York
| – | -$195K | -27 | Closed |
|
|
BA
54
BlackRock Advisors
Wilmington,
Delaware
| – | -$85K | -12 | Closed |
|
55
Morgan Stanley
New York
| – | -$38K | -5 | Closed |
|
56
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$3K | – | – |
|
EIGR Hedge Fund Activity: Q3 2014 in Review
45 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2014, worth a combined $123M — down 4% from $128M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new EIGR positions and 9 closed out — a net gain of 5 holders — while 14 added to existing stakes and 10 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $13.5M. The largest seller was Northern Trust, cutting an estimated $518K.
- 45 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2014, up from 40 in Q2 2014.
- Funds reported $123M of Eiger BioPharmaceuticals, Inc. stock for Q3 2014, down 4% quarter-over-quarter.
- 14 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2014 and 9 closed out, a net change of +5 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2014 was Eagle Asset Management, an estimated $13.5M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2014 was Northern Trust, an estimated $518K sold.
Based on aggregated 13F filings for Q3 2014.